NVO - Eli Lilly Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition | Benzinga
Shares of Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
What Happened: Pfizer has selected its preferred once-daily modified release formulation for danuglipron, a GLP-1 receptor agonist. This decision by Pfizer intensifies competition in the diabetes treatment ...